About Arvelle Therapeutics
Arvelle Therapeutics is a Healthcare company based in Zug (Switzerland) founded in 2019, and was acquired by Angelini Pharma in January 2021. Small molecule therapies are developed for partial-onset seizures treatment. Arvelle Therapeutics has raised $222.7 million across 2 funding rounds from investors including Angelini Pharma, Andera Partners and Life Sciences Partners. Its focus areas include Life Sciences, Neurology, Drugs and Epilepsy.
Company details
Arvelle Therapeutics was founded in 2019 in Zug, Switzerland. Small molecule therapies for central nervous system disorders are developed by the firm. The lead candidate, Cenobamate, is targeted at partial-onset seizures in adult patients via GABA-A receptor modulation and sodium current inhibition. Exclusive rights for European development and commercialization were acquired from SK Biopharmaceuticals. An NDA for Cenobamate was filed in February 2019.
- Headquarters Zug, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website arvelletx.com
- Social LinkedIn X Facebook
- Acquired by Angelini Pharma (Jan 2021)
- Total Equity Funding$222.7M (USD)
in 2 rounds
- Latest Funding Round$42.7M (USD), Series A
May 2020
- InvestorsAngelini Pharma
& 8 more
- Acquired byAngelini Pharma
(Jan 2021)
Funding Insights of Arvelle Therapeutics
Arvelle Therapeutics has successfully raised a total of $222.7M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $42.7 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $222.7M
- Total Rounds 2
- Last Round Series A — $42.7M
- First Round $180M
(Feb 2019)
- Investors Count 8
All 2 funding rounds of Arvelle Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $42.7M | Series A | – | NovaQuest Capital Management, BRV Capital Management | – |
| Feb 2019 | $180M | Series A | – | Life Sciences Partners |
9 investors in total: 9 institutional.
Investors in Arvelle Therapeutics
Arvelle Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Angelini Pharma, Andera Partners and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Manages diversified investment funds and portfolios for clients. | 2014 | brvcap.com | Wan Chai, China | |
| higbio.com | ||||
Gene therapies for rare pediatric neurodegenerative diseases are developed. | 2014 | siogtx.com | New York, United States | |
Manufacturer and developer of active ingredients, branded drugs, medical products and dietary supplements | 1919 | angelinipharma.com | Rome, Italy |
Investor details for Arvelle Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Arvelle Therapeutics
4 dated milestones of Arvelle Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Arvelle Therapeutics is founded.
- Funding First funding round of $180.0M.
- Funding Latest funding round, Series A, of $42.7M.
- Exit Acquired by Angelini Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arvelle Therapeutics
Complete news archive for Arvelle Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arvelle Therapeutics
Arvelle Therapeutics was founded in 2019.
Arvelle Therapeutics is headquartered in Zug, Switzerland. It is registered at Zug, Zug, Switzerland.
Arvelle Therapeutics is a funded company, having raised a total of $222.7M across 2 funding rounds to date. The company's 1st funding round was a Series A of $180M, raised on Feb 2019.
Arvelle Therapeutics was founded in 2019 in Zug, Switzerland. Small molecule therapies for central nervous system disorders are developed by the firm. The lead candidate, Cenobamate, is targeted at partial-onset seizures in adult patients via GABA-A receptor modulation and sodium current inhibition. Exclusive rights for European development and commercialization were acquired from SK Biopharmaceuticals. An NDA for Cenobamate was filed in February 2019.
Arvelle Therapeutics has 9 investors. Key investors include Angelini Pharma, Andera Partners, Life Sciences Partners, KB Investment, and Sio Gene Therapies.
Yes. Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.